AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 4 - (NewsRx.com & NewsRx.net) -- Researchers review molecular adjuvants for mucosal immunity in a recent issue of Immunological Reviews.
According to a study from the United States, "Mucosal surfaces represent the entry route of a multitude of viral pathogens. For many of these viruses, such as the herpes simplex viruses and human immunodeficiency virus, no effective vaccine exists. Hence, it is important that prospective vaccines engender maximal immunity at these susceptible sites. Genetic vaccines encoding adjuvant molecules represent one approach to optimize mucosal as well as systemic immunity."
"Promising candidates include various inflammatory cytokines and chemokines that might be used to enhance the primary response to a level sufficient for protection," said Felix N. Toka and collaborators at the University of Tennessee. "Encouraging studies involving cytokines such as granulocyte/macrophage colony-stimulating factor, interleukin-2 (IL-2), IL-12, IL-18, and many others are examined. Notable chemokines that may offer hope in such efforts include IL-8, RANTES, CCL19, CCL21, and a few others. Combinatorial approaches utilizing several cytokines and chemokines will most likely yield the greatest success."
"In addition, as more is discovered ...
Source: HighBeam Research, Molecular adjuvants for mucosal immunity reviewed.